The potential role of fowlpox virus in rational vaccine design

被引:23
作者
Beukema, Emma L.
Brown, Michael P.
Hayball, John D.
机构
[1] Univ S Australia, Sch Pharm & Med Sci, Samson Inst, Adelaide, SA 5000, Australia
[2] Hanson Inst, Expt Therapeut Lab, Adelaide, SA 5000, Australia
[3] Univ S Australia, Dept Med, Adelaide, SA 5000, Australia
[4] Royal Adelaide Hosp, Ctr Canc, Dept Oncol, Adelaide, SA 5000, Australia
基金
澳大利亚研究理事会;
关键词
antigen presentation; fowlpox virus; immune evasion; rational vaccine design; viral tropism;
D O I
10.1586/14760584.5.4.565
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The design of optimal vaccines requires detailed knowledge of how protective immune responses are generated in vivo under normal circumstances. This approach to vaccine development, where the immune correlates of protection are defined and vaccines are designed to elicit the same response, is called rational vaccine design. Poxviruses are attractive candidates for inclusion in such design strategies owing to their large genome, which allows for the inclusion of multiple heterologous genes, including those encoding antigens, co-stimulatory molecules and cytokines. Fowlpox virus, the prototypical member of the Avipoxvirus genus, is particularly suitable, as it is also incapable of replicating in mammalian cells. The potential of recombinant fowlpox virus as a safe vaccine vector is being evaluated currently in a number of clinical trials for diseases, including HIV, malaria and various types of cancer. Despite their promise, intricate details regarding how fowlpox virus interacts with the host immune system have not been resolved. In this review, the issues surrounding the use of fowlpox virus as a vaccine vector and possible strategies for enhancing its efficacy are discussed.
引用
收藏
页码:565 / 577
页数:13
相关论文
共 108 条
[51]   Proguss toward an HIV vaccine [J].
Letvin, NL .
ANNUAL REVIEW OF MEDICINE, 2005, 56 :213-223
[52]   Drug trials - Violent reaction to monoclonal antibody therapy remains a mystery [J].
Marshall, E .
SCIENCE, 2006, 311 (5768) :1688-1689
[53]   Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas [J].
Marshall, JL ;
Gulley, JL ;
Arlen, PM ;
Beetham, PK ;
Tsang, KY ;
Slack, R ;
Hodge, JW ;
Doren, S ;
Grosenbach, DW ;
Hwang, J ;
Fox, E ;
Odogwu, L ;
Park, S ;
Panicali, D ;
Schlom, J .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :720-731
[54]   Poxvirus tropism [J].
McFadden, G .
NATURE REVIEWS MICROBIOLOGY, 2005, 3 (03) :201-213
[55]   Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in gambian men [J].
Moorthy, VS ;
Imoukhuede, EB ;
Keating, S ;
Pinder, M ;
Webster, D ;
Skinner, MA ;
Gilbert, SC ;
Walraven, G ;
Hill, AVS .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (12) :2213-2219
[56]   Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety [J].
Moss, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (21) :11341-11348
[57]  
MOSS B, 1990, POXVIRIDAE THEIR REP
[58]   SPECIES-SPECIFICITY OF ECTROMELIA VIRUS AND VACCINIA VIRUS INTERFERON-GAMMA BINDING-PROTEINS [J].
MOSSMAN, K ;
UPTON, C ;
BULLER, RML ;
MCFADDEN, G .
VIROLOGY, 1995, 208 (02) :762-769
[59]   Creation of killer poxvirus could have been predicted [J].
Müllbacher, A ;
Lobigs, M .
JOURNAL OF VIROLOGY, 2001, 75 (18) :8353-8355
[60]   Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells [J].
Napolitani, G ;
Rinaldi, A ;
Bertoni, F ;
Sallusto, F ;
Lanzavecchia, A .
NATURE IMMUNOLOGY, 2005, 6 (08) :769-776